STAT and Soundcloud feature Jason Karlawish in a podcast. Karlawish argues that new promising drugs like lecanemab, an anti-amyloid antibody expected to be approved by the FDA July 6, will introduce complicated issues into the field of Alzheimer's care. These medications require a great deal of testing and patient monitoring, trained physicians, and other resources in a system that is already stretched thin.
Citations:
"Listen: Is the medical system ready for Alzheimer’s drugs that work?" STAT, T Bosch, July 5, 2023.
"First Opinion Podcast: Episode 80: Is the medical system ready for Alzheimer's drugs that work?" Soundcloud, July 5, 2023.
"The FDA needs a risk evaluation and mitigation strategy for Alzheimer’s drug lecanemab." STAT, J Karlawish, June 16, 2023.